Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK44459 in Behçet's Disease (Extension Study)
NCT07070739Phase 2Not yet recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of HSK44459 in Behçet's disease (BD), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Incidence and severity of adverse events at 56 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
HSK44459
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT07070739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070739.